Mark J. Gergen - 02 Jan 2024 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role: Executive Chairman, Director
Signature: /s/ Harry J.Leonhardt, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 02 Jan 2024
Net transactions value: $0
Form type: 4
Filing time: 04 Jan 2024, 16:02:14 UTC
Previous filing: 02 Mar 2023
Next filing: 02 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Award	$0	+125,000	+21%	$0.000000	732,610	02 Jan 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Stock Option (Right to buy)	Award	$0	+172,600		$0.000000	172,600	02 Jan 2024	Common Stock	172,600	$3.38	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest 50% on each of the one-year and two-year anniversary of January 1, 2024.
F2	Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2023 and 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2023.
F3	25% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of January 1, 2024, and the remaining shares will vest in 18 equal monthly installments thereafter.